Month: September 2026

Media Relations:
Sam Connatty
Tel.: +44 (0) 7811 486517
E-Mail: sam.connatty@capgemini.com

Capgemini closes the sale of Capgemini Government Solutions

Paris, September 30, 2026 – The sale of Capgemini Government Solutions (CGS) to ITC Federal completed today, pursuant to the definitive agreement announced on September 12, 2026.

About Capgemini
Capgemini is the business transformation partner for enterprises in the age of AI. We help organizations imagine and build an intelligent, sustainable future, combining AI, technology and human ingenuity to transform how they operate, innovate and grow. With unique end-to-end capabilities spanning strategy, technology, engineering and intelligent operations, we bring together deep industry expertise and market-leading capabilities in AI, cloud and data to turn ambition into measurable business outcomes at scale. Supported by a robust ecosystem of partners and nearly 60 years of expertise, Capgemini is a responsible and diverse global organization of over 410,000 team members in more than 50 countries. The Group reported 2025 revenues of €22.5 billion.

Make it real | www.capgemini.com

Attachment

• 09_30 Closing of Capgemini Government Solutions divestment

Approximately 78% of global workforce volunteers in CSR initiatives as Scope 1 and 2 emissions reductions fall 64% from 2019 baseline

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a global data and AI company, announced the publication of its seventh annual Sustainability Report, Embedding Sustainability. The report details EXL’s sustainability progress during 2025, underscoring the company’s commitment to go beyond standard business practices and embed sustainability as a driver of long-term value for clients, employees, communities and shareholders.

EXL’s 2025 Sustainability Report reflects a year of measurable progress against the company’s baseline commitments, the expansion of community and education initiatives, and the deepening integration of responsible AI and data governance principles.

“At EXL, sustainability is not a side initiative; it is central to how we build a stronger, more resilient business,” said Ajay Ayyappan, executive vice president and general counsel, EXL. “Our Sustainability Report reflects the belief that has guided EXL from the beginning: there is always a better way. We go beyond to make it happen. This year’s report demonstrates that mindset in action, from industry-leading employee participation in volunteering and giving to meaningful progress in reducing greenhouse gas emissions against our 2019 baseline.”

In 2025, EXL advanced across every dimension of its sustainability agenda, deepening emissions reductions against the 2019 baseline, scaling industry-leading employee participation in volunteering and community investment, and maturing its Responsible and Secure AI program.

Key highlights include:

• ∼78% of EXL’s global workforce participated in volunteering and giving — an industry-leading level of engagement — contributing nearly 100,000 volunteer hours benefiting more than 139,000 individuals worldwide
• ∼64% decrease in combined Scope 1 and 2 GHG emissions since the 2019 baseline, alongside a ∼19% decrease in Scope 3 emissions
• ∼54% renewable energy across EXL’s global energy portfolio, up from 44% in 2024, with ∼74% of operational space in green or LEED-certified facilities
• Achieved ISO 42001 certification for AI management systems

EXL prepared its 2025 Sustainability Report in accordance with the Global Reporting Initiative Standards and the Sustainability Accounting Standards Board Software and IT Services Standard, with climate-related disclosures aligned to the recommendations of the Task Force on Climate-related Financial Disclosures. EXL’s reporting also maps to the United Nations Sustainable Development Goals and reflects the company’s commitment to the United Nations Global Compact.

The full report is available at www.exlservice.com/about/sustainability.

About EXL

EXL (NASDAQ: EXLS) is a global data and AI company that offers services and solutions to reinvent client business models, drive better outcomes and unlock growth with speed. EXL propels enterprises to go beyond AI ambition to impact by combining the power of data, AI, and deep industry context with trusted execution. Our clients include the world’s leading corporations across insurance, healthcare, banking and capital markets, retail, communications and media, and energy and infrastructure, among others. EXL was founded in 1999 with the core values of innovation, collaboration, excellence, integrity and respect. We are headquartered in New York and have approximately 68,000 employees spanning six continents. For more information, visit http://www.exlservice.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to EXL’s operations and business environment, all of which are difficult to predict and many of which are beyond EXL’s control. Forward-looking statements include information concerning EXL’s possible or assumed future results of operations, including descriptions of its business strategy. These statements may include words such as “may,” “will,” “should,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or similar expressions. These statements are based on assumptions that we have made in light of management’s experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although EXL believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect EXL’s actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors, which include our ability to maintain and grow client demand, our ability to hire and retain sufficiently trained employees, and our ability to accurately estimate and/or manage costs, rising interest rates, rising inflation and recessionary economic trends, are discussed in more detail in EXL’s filings with the Securities and Exchange Commission, including EXL’s Annual Report on Form 10-K. You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or how they may affect EXL. EXL has no obligation to update any forward-looking statements after the date hereof, except as required by federal securities laws.

Contact:
Keith Little
Head of Public Relations
media.relations@exlservice.com

PRESS RELEASE

Bloomberg (THEON:NA) / Reuters (THEON.AS)

30 September 2026 – Theon International Plc (THEON)  is pleased to announce it has been awarded various contracts for a total value of c.€50 million from European and Middle Eastern countries, with deliveries expected to commence this year.

More specifically, Theon received the notification of award for the supply of its NYX night vision goggles and the ORION fused goggles to a European NATO Member state. This is the first major contract award for the ORION fused goggles from a western European end user, which is a significant step in the context of the THEON NEXT initiative to develop a European, fully interconnected future soldier vision system.

Alongside the above, further orders have been received by KAPPA (100% owned by THEON) for various land and sea applications for a high single-digit million amount in total.

Remaining orders reflecting a mix of man portable products. As we enter Q4 2026, the reprioritization towards land forces equipment anticipated by THEON earlier this year is already materialising, with THEON being selected across various projects.

These orders further reinforce THEON’s leadership position in the evolving soldier modernisation era, and we continue to expect demand to accelerate in Q4 this year and into early 2027.

Philippe Mennicken, Deputy CEO and Business Development Director of THEON stated: “We are pleased to see demand indicators across the board for the coming periods to point in the right direction as shown by the first batch of new orders and as already advised on reprioritisation in progress. With THEON’s selection across several other higher-value contracts and options, we expect to deliver strong last quarter 2026/first quarter 2027 (depending on approval processes by several governments) order intake, but like always we continue to remain conservative in our approach. Last, but not least, we are also pleased that our Business Development & R&D integration activities for the recent investments and acquisitions continue, especially for gimbals and air defence systems. While full operational integration can only commence following the receipt of required regulatory approvals, THEON has already commenced offering an integrated electro-optical platform globally, through these initial integration activities. “

For inquiries, please contact:

Investor Relations Nikos Malesiotis E-Mail: ir@theon.com Tel: +30 210 6772290

Media Contact Elli Michou E-Mail: press@theon.com Tel: +30 210 6728610

About THEON GROUP

THEON GROUP of companies develops and manufactures cutting-edge night vision and thermal imaging systems for Defense and Security applications with a global footprint. THEON GROUP started its operations in 1997 from Greece and today occupies a leading role in the sector thanks to its international presence through subsidiaries and production facilities in Greece, Cyprus, Germany, the Baltics, the United States, the Gulf States, Switzerland, Denmark, Belgium, Singapore and South Korea. THEON GROUP has more than 300,000 systems in service with Armed and Special Forces in 73 countries around the world, 26 of which are NATO countries. ΤΗΕΟΝ ΙΝΤΕRNATIONAL PLC has been listed on Euronext Amsterdam (AMS: THEON) since February 2024.
www.theon.com

        

Attachment

• Press Release New Orders Sep 2026_vF

Extension of consents from RCF and Quatrim creditors
and of the maturity of the operational financings

Paris, 30 September 2026

Further to its press release dated 27 July 2026¹, the Group announces that it has obtained from its RCF and Quatrim creditors an extension of their consent not to use the current discussions regarding the adaptation and strengthening project of the Group’s financial structure as any means of action in respect of (i) the financing documentation forming an integral part of the accelerated safeguard plans or (ii) the approved operational financing documentation under the conciliation protocols.

The RCF, operational financings and Quatrim consents are now valid until 31 October 2026, with an option to extend to 15 November 2026 in the event of the signing of a binding agreement by 31 October 2026 with Quatrim creditors.

The consents relating to the RCF, operational financings and Quatrim also include a standstill on any right arising from the non-payment of the TLB interest due on 27 September 2026, as announced by Casino in its press release dated 24 September 2026².

Furthermore, the Group indicates that it has obtained from relevant creditors an extension of the maturity of its operational financings until 15 November 2026, except for the RCF Monoprix Exploitation, the maturity of which has been postponed to 16 November 2026.

***

ANALYSTS AND INVESTORS CONTACTS

Charlotte IZABEL – cizabel@groupe-casino.fr – Tél : +33 (0)6 89 19 88 33

IR_Casino@groupe-casino.fr – Tél : +33 (0)1 53 65 24 17

PRESS CONTACTS

Casino Group – Communications Department

Stéphanie ABADIE – sabadie@groupe-casino.fr – Tél : +33 (0)6 26 27 37 05

directiondelacommunication@groupe-casino.fr – Tél : + 33(0) 1 53 65 24 29

---

¹ Press release dated 27 July 2026
² Press release dated 24 September 2026

Attachment

• 2026-09-30 – PR – Casino Communication

Fontaine Vitale represents a significant new market and revenue opportunity for Celularity in the Asia-Pacific region

FLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today highlighted continued progress at Fontaine Vitale, a regenerative medicine and wellness center being developed in the Sanur Special Economic Zone (“Sanur SEZ”) in Bali, Indonesia, in anticipation of its grand opening in the first quarter of 2027.

Developed by Genting Berhad and its Indonesian partners with strategic collaboration and input from Celularity, Fontaine Vitale is designed to serve local and international patients seeking advanced wellness, aesthetics, longevity and regenerative medicine services at a four-story facility of an approximately 172,000-square feet with extensive landscaped gardens, Balinese inspired design and modern amenities. Learn more at https://fontainevitale.com/.

Fontaine Vitale is expected to be the first facility in the ASEAN region to offer placenta-derived allogeneic stem cell therapy, leveraging Celularity’s technology and products manufactured at the Company’s cGMP research and manufacturing facility in Florham Park, New Jersey. Celularity expects to supply its placenta-derived platform of products to Fontaine Vitale, subject to final commercial arrangements, applicable regulatory authorizations, treatment protocols and market conditions.

New Market and Revenue Opportunity

Fontaine Vitale is designed to accommodate physician-directed treatments for local and international patients. As the facility builds utilization following its opening, Celularity believes it represents a significant new market and revenue opportunity for the Company.

“The excitement building around the anticipated grand opening of Fontaine Vitale is extraordinary, and the facility coming up looks amazing,” said Robert J. Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity. “For Celularity, Fontaine Vitale represents a platform for introducing our placenta-derived cellular technology to patients throughout Indonesia and the broader Asia-Pacific region.”

Dr. Hariri continued, “Importantly, we believe Celularity is well positioned to support the growth of Fontaine Vitale making it a leading destination for novel regenerative therapeutic products. Together with Genting, we aspire to build a model for regenerative longevity that brings scientific innovation closer to patients and helps shape how these therapies are responsibly deployed around the world.”

Fontaine Vitale is expected to initially offer physician-directed services focused on wellness and resilience, anti-aging and vitality, musculoskeletal and mobility support, and aesthetic and skin rejuvenation. The facility is located within the Sanur SEZ, Indonesia’s first medical-tourism special economic zone, which is being developed as an integrated international healthcare, wellness and hospitality destination.

About Celularity

Celularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and cellular medicine company developing and manufacturing allogeneic and autologous cell therapies derived from the postpartum placenta. Celularity draws on the placenta’s unique biology, immunologic properties and scalable availability to develop therapeutic solutions targeting fundamental mechanisms of aging and age-related disease. Its cellular therapy portfolio includes cenplacel-L, its investigational placenta-derived allogeneic cell therapy, and other investigational cellular therapies. Celularity is headquartered in Florham Park, New Jersey, where it operates a purpose-built cGMP research and manufacturing facility supporting the development and manufacture of cellular therapies, advanced biomaterials and other longevity and wellness-focused products.

For more information, please visit: www.celularity.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. These statements include, without limitation, statements regarding the anticipated January 2027 opening and commencement of operations at Fontaine Vitale; its planned services, capabilities and potential position in the ASEAN regenerative medicine market; Celularity’s anticipated supply of cellular products and the completion of related commercial arrangements; expected patient demand, facility utilization and growth; potential market and revenue opportunities; and the expansion of access to Celularity’s technology and products in Indonesia and the broader Asia-Pacific region. These statements are based on management’s current expectations and assumptions and are not guarantees of future performance.

Actual results could differ materially due to risks and uncertainties, including delays in completing, licensing or opening Fontaine Vitale; the ability to obtain and maintain applicable authorizations for the importation, supply and use of cellular products in Indonesia; changes in laws, regulations or policies governing regenerative medicine, medical tourism or the Sanur Special Economic Zone; the ability to finalize and implement commercial arrangements and treatment protocols; the performance of Genting, Fontaine Vitale and other third parties on which the opportunity depends; the timing and extent of physician and patient adoption, international patient travel and facility utilization; actual order volumes, pricing and payment terms; manufacturing capacity, product quality, release requirements, shelf life and cross-border transport and storage; clinical safety and efficacy uncertainties associated with investigational cellular therapies; and Celularity’s ability to obtain sufficient funding, meet its obligations and maintain the personnel and infrastructure necessary to support these activities. The anticipated opening of Fontaine Vitale does not assure that Celularity will receive product orders or generate revenue, and any revenue may be delayed or lower than anticipated.

Additional risks are described under “Risk Factors” and elsewhere in Celularity’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Forward-looking statements speak only as of the date of this release, and readers should not place undue reliance on them. Except as required by law, Celularity undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor and Media Contact:
info@celularity.com